Aptinyx Receives FDA Fast Track Designation for Development of NYX-2925 as Treatment for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

EVANSTON, Ill., Sept. 13, 2016 -- (Healthcare Sales & Marketing Network) -- Aptinyx Inc., a biopharmaceutical company developing novel modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging neurologic disorders, today anno... Biopharmaceuticals, Neurology, FDA Aptinyx, NMDA, Neuropathic Pain, Diabetic Peripheral Neuropathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news